Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ralph Lauren Corp (RL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ralph Lauren Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Ralph Lauren Corp trades at $393.26 (market cap $23.50B). The key difference: Ralph Lauren Corp is far larger — about 28.4× Amphastar Pharmaceuticals Inc's market cap, and Ralph Lauren Corp pays a 0.95% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | RL | |
|---|---|---|
Market Cap | $826.08M | $23.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $414.25 |
52-Week Low | $16.87 | $283.34 |
Enterprise Value | $1.22B | $24.45B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Ralph Lauren (RL) trades at $394.9, up 1.89% today, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows strong fundamentals with a 10.49% net income margin and 34.66% ROE, though technical indicators signal near-term bearish pressure. Recent news highlights brand momentum in Asia and digital expansion under its Next Great Chapter plan, supporting growth prospects.
The outlook is positive given consistent earnings beats and analyst consensus favoring a buy rating with a $446.25 price target, implying 13% upside. Key risks include premium valuation multiples and macroeconomic headwinds affecting consumer discretionary spending, but strong cash flow and margin expansion provide a solid foundation for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
